Australia: Microba Life Sciences completes A$30m IPO on ASX

Australian-based commercial stage company with technology for measuring the human gut microbiome, Microba Life Sciences, has raised A$30m (US$22.9m) with an IPO on ASX. Shares were offered at A$0.45 per share, which gives the company a market capitalisation of around A$123m (on an undiluted basis). Bell Potter Securities and Canaccord Genuity were joint lead managers…

You must be a HMI Subscriber to view this content.

Subscribe Now »